In the VIALE-A study, a phase 1b study, which proved the clinical efficacy of venetoclax in combination with azacitidine for previously untreated AML, the subgroup analysis suggested that IDH1 and IDH2 mutations were independently associated with a favorable prognosis (hazard ratio, 0.34) [42]. This evidence concerns the gene IDH1 and acute myeloid leukemia.